21st Century Oncology Holdings, Inc., together with its subsidiaries, operates as a physician-led provider of integrated cancer care services. Its radiation treatment services include external beam therapies, such as conformal radiation therapy, intensity modulated radiation therapy, and stereotactic radiosurgery, as well as internal radiation therapies, such as high-dose and low-dose rate brachytherapies. The company’s radiation treatment services also comprise image guided radiation therapy, Gamma function testing, and respiratory gating. In addition, it offers support services in the areas of psychological and nutritional counseling, as well as transportation assistance. Further, the comp...
2270 Colonial Boulevard
Fort Myers, FL 33907
Founded in 1983
21st Century Oncology Holdings, Inc. Appoints Leanne M. Stewart as Chief Financial Officer Effective September 14, 2015
Sep 4 15
On September 4, 2015, 21st Century Oncology Holdings, Inc. appointed LeAnne M. Stewart as Chief Financial Officer of the Company, effective September 14, 2015. Ms. Stewart, age 50, previously served as Chief Financial Officer of CRC Health Group. In February 2015, CRC was sold to a strategic buyer. Previously, Ms. Stewart was Senior Vice President and Chief Financial Officer of Granite Construction from 2008 to 2010. From 1999 through 2007, Ms. Stewart held various roles at Nash Finch Company, including Senior Vice President and Chief Financial Officer from 2004 to 2007 and Vice President and Corporate Controller from 2000 to 2004.
21st Century Oncology Holdings, Inc. Announces Auditor Changes
Aug 28 15
On August 25, 2015, 21st Century Oncology Holdings, Inc. notified that Deloitte & Touche LLP was dismissed as the company's independent registered public accounting firm. Deloitte's dismissal became effective on August 25, 2015. On August 25, 2015, the company approved the engagement of Ernst & Young LLP as the company's new independent registered public accounting firm.
21st Century Oncology Holdings, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for Second Half and Full Year of 2015
Aug 11 15
21st Century Oncology Holdings, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, total revenues were $285,209,000 against $265,898,000 a year ago. Loss before income taxes was $59,375,000 against $203,665,000 a year ago. Net loss attributable to the company’s shareholder was $64,538,000 against $207,524,000 a year ago. Total pro-forma revenues $285,209,000 against $265,898,000 a year ago. Pro-forma Adjusted EBITDA was $51,099,000 against $43,197,000 a year ago.
For the six months, total revenues were $563,692,000 against $499,295,000 a year ago. Loss before income taxes was $69,619,000 against $230,804,000 a year ago. Net loss attributable to the company’s shareholder $79,780,000 against $237,705,000 a year ago. Net cash provided by operating activities was $13,036,000 against $9,869,000 a year ago. Purchase of property and equipment was $25,753,000 against $33,147,000 a year ago. Total pro-forma revenues $563,692,000 against $508,114,000 a year ago. Pro-forma Adjusted EBITDA was $94,779,000 against $76,556,000 a year ago.
For the second half of 2015, the company expects to have positive free cash flow defined as pro forma adjusted EBITDA less cash add-backs, interest payments, cash capital expenditures and cash taxes.
For the full year 2015 the company expects pro forma adjusted EBITDA guidance between $182 million and $190 million. The capital expenditure guidance for the full year 2015 is approximately $45 million.